Literature DB >> 25054815

First-line bevacizumab for glioblastoma: what do recent Trail results mean for future treatment?

Christine Marosi1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 25054815      PMCID: PMC6136101          DOI: 10.2217/cns.13.41

Source DB:  PubMed          Journal:  CNS Oncol        ISSN: 2045-0907


× No keyword cloud information.
  2 in total

1.  Glioblastoma survival in the United States improved after Food and Drug Administration approval of bevacizumab: a population-based analysis.

Authors:  Derek R Johnson; Heather E Leeper; Joon H Uhm
Journal:  Cancer       Date:  2013-07-18       Impact factor: 6.860

2.  Hypoxia and hypoxia-inducible factor-1 target genes in central nervous system radiation injury: a role for vascular endothelial growth factor.

Authors:  Robert A Nordal; Andras Nagy; Melania Pintilie; C Shun Wong
Journal:  Clin Cancer Res       Date:  2004-05-15       Impact factor: 12.531

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.